NUCB2 and nasopharyngeal carcinoma: Tumour regions enriched with NUCB2‐expressing NPC‐like populations may exhibit enhanced sensitivity to such targeted therapies, whereas areas dominated by NUCB2‐low cellular subsets could maintain their resistance to treatment.